Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135].

Trial Profile

Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135].

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Contusugene ladenovec (Primary) ; Contusugene ladenovec (Primary)
  • Indications Head and neck cancer; Mouth disorders; Pharyngeal disorders
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov (NCT00064103).
    • 22 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov (NCT00064103).
    • 29 Nov 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov. (NCT00410865).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top